AzTrials
AzTrials

Erectile DysfunctionNCT05439486

New Treatment in Erectile Dysfunction Patients.

A study testing hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber. in people with Erectile Dysfunction, run by Sohag University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record

Search all trials

Trial summary

Erectile dysfunction patients who are non responder to sildenafil will be treated with hyperbaric oxygen therapy with 100% concentration and at 2 ATM for 30 consecutive sessions each one 90 minutes and then will be reassessed. Read more about this study

Who is it for?
Any age, men only
Conditions the study is for
Erectile Dysfunction
What is being tested?
hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
30 participants
Where
1 siteEgypt
Study dates
29 Jan 2022to 29 Oct 2022
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Men only
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Patients with regular sexual relationship in the last 6 months
  • having organic ED and
  • non responder to Sildenafil were included in our study.

Who cannot join

  • Hypogonadism,
  • History of Pelvic trauma, surgery or disease,
  • Receiving treatment in the last 3 months,
  • History of premature ejaculation,
  • History of spinal cord or brain disease,
  • History of drug abuse,
Show all 10Show fewer
  • Patients without a regular sexual partner,
  • Patients with advanced kidney disease (creatinine>1.3 mg\dl) or liver disease,
  • History of psychiatric diseases,
  • HBOT exclusion as open pneumo-thorax, chest disease, sezure and congestive heart failure.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Faculty of medicine sohag university

    Sohag

Other trials in Egypt

About this study

Official title: Evaluation the Efficacy and Safety of Hyperbaric Oxygen Therapy in Sildenafil Non Responder Erectile Dysfunction Patients.

Erectile dysfunction patients who are non responder to sildenafil will be treated with hyperbaric oxygen therapy with 100% concentration and at 2 ATM for 30 consecutive sessions each one 90 minutes and then will be reassessed.

Read the detailed description

This study is double blinded randomized controlled clinical trial that includes organic ED patients who attend to the Andrology out patient clinics, Department of Dermatology, Venerology and Andrology, Sohag University hospital, Sohag, Egypt. Informed consent was obtained from all patients. The study was submitted for approval by Ethical and Research committees at Sohag Faculty of Medicine, Sohag University, Sohag, Egypt.

Study design:

Patients were divided into two groups (randomly assigned and comparably cross matched for age). Both patients and the investigators were blinded as regard the treatment until the end of the study.

Group 1: Patients assigned to the HBOT group were treated with (30) sessions in consecutive days (90 minutes of 100% oxygen at 2.2 ATM).

Group 1: Patients assigned to control group were exposed to (30) sessions of air oxygen tension at 2.2 ATM.

All patients were subjected to the following:

  1. Medical history:
  • Personal history: Age, residence, marital status, occupation and special habits of medical importance.
  • ED history: Onset, course and duration.
  • Sexual History: duration of marriage, wife age, frequency of intercourse, morning erection, orgasm, libido, percent of weakness, type and dose of PDE5I and its response after proper instructions and ejaculation.
  • Medical history : History of medical diseases (Hypertension, Diabetes mellitus, Liver disease and any chronic disease).
  • Therapeutic history: previous ED treatment modalities and response to them in addition to other current drug intake.
  • Past history of operations.
  1. General examination: It included height, weight, BMI, Blood Pressure, hair distribution, fat distribution and breast examination. Blood pressure and pulse.
  2. Local examination: Penis: (stretched flaccid length, urethral meatus, deformities and fibrosis). Testes: (site, size, consistency). Spermatic cord. Any scar of previous operations.
  3. Erectile function evaluation: 4-1- Arabic version of the sexual health inventory for men (SHIM): The SHIM is a five-item scale in which each item is scored from 0 to 5 on four items and 1 to 5 on one item. It includes four of the six items from the original erectile function domain of the IIEF and includes items in maintenance ability, erection confidence, maintenance frequency and erection firmness in addition to a single item on intercourse satisfaction. Among men in a relationship with a partner, including those men who have opportunity but no desire to attempt sexual activity or intercourse. Disease grades of ED on SHIM scores were categorized as follows: severe ED (SHIM score:1-7), moderate ED (8-11), mild-to-moderate ED(12-16), mild (17-21), and no ED (22-25). A cut off value of 21 was chosen, so that patients with scores of 21 or less were classified as having had ED while patients with scores above 21were classified as having no ED. 4-2- Arabic version of Erection Hardness Score (EHS): The EHS is a single-item instrument that asks men to rate erection hardness on a scale that ranges from 0 (penis does not enlarge) to 4 (penis is completely hard and fully rigid). 4-3- The sexual health encounter profile (SEP- Questions 2 and 3): The treatment efficacy evaluated through asking the patients to answer the SEP-Q2 and SEP-Q3 with yes or no. SEP-Q2: Were you able to insert your penis into your partner's vagina? SEP-Q3: Did your erection last long enough for you to have successful intercourse? 4-4- Penile color Doppler: Patients evaluated by penile color Doppler after intra-cavernosal injection of 1 ml of Prostaglandin E1 (10 µg/ml). Key parameters included PSV, (cavernosal artery blood flow rate at start of systole) and EDV, (cavernosal artery blood flow rate at the end of diastole. PSV <30 cm/s is considered evidence of arterial insufficiency (arteriogenic ED) and EDV >5 cm/s is consistent with venoocclusive ED. RI (defined as PSV-EDV/PSV) is an indicator for venoocclusive function assessment. RI >0.80 have been cited as indicative of normal veno-occlusive function.
  4. Laboratory investigations: Patients evaluated with random blood sugar, lipid profile after 12 hours fasting, and serum uric acid. A morning 8:00- 10:00 a.m. blood sample collected for measurement of total and free testosterone.
  5. Safety evaluation: Safety and tolerability evaluated throughout the course of the study by assessing adverse events reported by either the patient or the physician.
  6. Follow up evaluation:

Patients evaluated at 3 points as follow:

The first initial evaluation, The second evaluation at the end of sessions and The third evaluation 3months after stoppage of sessions.

The evaluation tools were as follow:

Erectile function evaluation: SHIM- EHS- SEP- Penile color Doppler, Laboratory evaluation: Total and free testosterone and Safety evaluation.

Outcome measures:

The outcome measures were: SHIM- EHS- SEP- penile Doppler parameters - response to PDE5i- reported side effects by physician and /or patients.

Statistical analysis:

Data analyzed using Statistical Package for Social Sciences SPSS) software program (version 16). All variables checked for normality.

Quantitative variables with normal distribution presented as means ± standard deviation (SD). While quantitative variables with no normal distribution presented as median (25th-75th percentile). Qualitative variables recorded as frequencies and percentages .

Comparison between continuous variables with normal distribution done by student t- test, while continuous variables with no normal distribution done by Mann-Whitney test. Qualitative variables compared by chi-square test.

Correlations between different variable performed when indicated with appropriate tests. Regression analysis done if indicated.

P value < 0.05 considered significant.

Being tested
hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.
Medical subject headings
Erectile Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.Device

    ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.

Study groups in NCT05439486
Study groupRoleWhat they receive
100% oxygenActive comparatorED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
Receives: Device: hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.
ordinary room oxygenPlacebo comparatorED patients in this group exposed to normal air oxygen concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
Receives: Device: hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in sexual health inventory for men (SHIM)

    The SHIM is a five-item scale in which each item is scored from 0 to 5 on four items and 1 to 5 on one item. It includes four of the six items from the original erectile function domain of the IIEF and includes items in maintenance ability, erection confidence, maintenance frequency and erection firmness in addition to a single item on intercourse satisfaction.

    Among men in a relationship with a partner, including those men who have opportunity but no desire to attempt sexual activity or intercourse.

    Disease grades of ED on SHIM scores were categorized as follows: severe ED (SHIM score:1-7), moderate ED (8-11), mild-to-moderate ED(12-16), mild (17-21), and no ED (22-25). A cut off value of 21 was chosen, so that patients with scores of 21 or less were classified as having had ED while patients with scores above 21were classified as having no ED (Shamloul et al., 2004).

    Measured: Base line ( before the sessions), at the end of sessions (6 weeks after ) and then 3 months after.

  2. Change in Erection Hardness Score (EHS)

    The EHS is a single-item instrument that asks men to rate erection hardness on a scale that ranges from 0 (penis does not enlarge) to 4 (penis is completely hard and fully rigid) (Arafa and Shamloul, 2009).

    Measured: Base line ( before the sessions), at the end of sessions (6 weeks after ) and then 3 months after.

  3. Change in the Sexual health encounter profile (SEP- Questions 2 and 3):

    The treatment efficacy evaluated through asking the patients to answer the SEP-Q2 and SEP-Q3 with yes or no (Tsetsvadz A. et al., 2009).

    SEP-Q2: Were you able to insert your penis into your partner's vagina? SEP-Q3: Did your erection last long enough for you to have successful intercourse?

    Measured: Base line ( before the sessions), at the end of sessions (6 weeks after ) and then 3 months after.

Secondary outcomes (1)
  1. Change in Penile color Doppler:

    Patients evaluated by penile color Doppler after intra-cavernosal injection of 1 ml of Prostaglandin E1 (10 µg/ml). Key parameters included PSV, (cavernosal artery blood flow rate at start of systole) and EDV, (cavernosal artery blood flow rate at the end of diastole) (Souper et al., 2017).

    PSV <30 cm/s is considered evidence of arterial insufficiency (arteriogenic ED) and EDV >5 cm/s is consistent with venoocclusive ED.

    RI (defined as PSV-EDV/PSV) is an indicator for venoocclusive function assessment. RI >0.80 have been cited as indicative of normal veno-occlusive function (Papagiannopoulos et al., 2015).

    Measured: Base line ( before the sessions), at the end of sessions (6 weeks after ) and then 3 months after.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jun 2022
  2. Study start29 Jan 2022
  3. Primary completion29 Aug 2022 (estimated)
  4. Study completion29 Oct 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double blinded randomized controlled trial
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05439486
Sponsor's protocol ID
Soh-Med-22-01-38
Status last verified
Jun 2022
First submitted
20 May 2022
Last updated
30 Jun 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in